Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07493304 · ClinicalTrials.gov registry record · Phase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,600
- Enrollment target
NCT07493304: Recruiting Phase 3 study, sponsored by Regeneron Pharmaceuticals.
NCT07493304 is a Phase 3 study that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,600 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07493304, a Phase 3 study, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,600 participants
- Enrollment target
Study Summary
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lungs (also called Pulmonary Embolism \[PE\]) (Part 2). The aim of the study is to see how safe and effective the study drug is at treating and preventing further blood clots in participants with or without cancer (Part 1) or in participants with cancer (Part 2) compared with another treatment (apixaban). The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Primary Outcome
Part 1
Interventions
- DRUG Apixaban
- DRUG REGN7508
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2031-07-08 |
| Phase | Phase 3 |
What NCT07493304 shows while recruiting
NCT07493304 is an interventional study that assigns participants to a tested intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT07493304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07493304 about?
NCT07493304 is a clinical study titled "Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers". This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that block blood flow (Part ...
What is the current status of trial NCT07493304?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,600 participants. The study started on 2026-06-30. Estimated completion is 2031-07-08.
What interventions are being tested in trial NCT07493304?
The interventions under investigation include: Apixaban (DRUG), REGN7508 (DRUG).
Who is sponsoring clinical trial NCT07493304?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07493304's enrollment target sits among peer trials
1,600 142nd of 2000 higher than 1,855 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI